Recce Pharmaceuticals in Position to Benefit from US ASPR Medical Countermeasures Strategy

MT Newswires Live

Jul 30

Recce Pharmaceuticals (ASX:RCE) said it was well positioned to benefit from the US Administration for Strategic Preparedness and Response's (ASPR) new five-year medical countermeasures funding strategy, which ranked antimicrobial resistance the second-highest funding priority in the plan, with $4.46 billion earmarked for broad-spectrum antimicrobials, according to a Thursday Australian bourse filing.

The funding aims to help antimicrobial candidates through each development stage, from preclinical research through to clinical trials and regulatory approval.

The firm's RECCE 327 treatment candidate has shown activity against a number of pathogen classes under its existing US Department of War programs, the filing noted.

Its shares rose 1% in recent trading on Thursday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/2655984624"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2655984624\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2655984624?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-30 09:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2655984624","market":"sh","top_or_hot":-1,"title":"Recce Pharmaceuticals in Position to Benefit from US ASPR Medical Countermeasures Strategy","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/RECEF\">Recce Pharmaceuticals</a> (ASX:RCE) said it was well positioned to benefit from the US Administration for Strategic Preparedness and Response's (ASPR) new five-year medical countermeasures funding strategy, which ranked antimicrobial resistance the second-highest funding priority in the plan, with $4.46 billion earmarked for broad-spectrum antimicrobials, according to a Thursday Australian bourse filing.</p><p>The funding aims to help antimicrobial candidates through each development stage, from preclinical research through to clinical trials and regulatory approval.</p><p>The firm's RECCE 327 treatment candidate has shown activity against a number of pathogen classes under its existing US Department of War programs, the filing noted.</p><p>Its shares rose 1% in recent trading on Thursday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Recce Pharmaceuticals in Position to Benefit from US ASPR Medical Countermeasures Strategy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRecce Pharmaceuticals in Position to Benefit from US ASPR Medical Countermeasures Strategy\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-07-30 09:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/RECEF\">Recce Pharmaceuticals</a> (ASX:RCE) said it was well positioned to benefit from the US Administration for Strategic Preparedness and Response's (ASPR) new five-year medical countermeasures funding strategy, which ranked antimicrobial resistance the second-highest funding priority in the plan, with $4.46 billion earmarked for broad-spectrum antimicrobials, according to a Thursday Australian bourse filing.</p><p>The funding aims to help antimicrobial candidates through each development stage, from preclinical research through to clinical trials and regulatory approval.</p><p>The firm's RECCE 327 treatment candidate has shown activity against a number of pathogen classes under its existing US Department of War programs, the filing noted.</p><p>Its shares rose 1% in recent trading on Thursday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4009","symbol_name":"广告","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2655984624","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2655984624","pubTimestamp":1785376729,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Recce Pharmaceuticals  said it was well positioned to benefit from the US Administration for Strategic Preparedness and Response's  new five-year medical countermeasures funding strategy, which ranked antimicrobial resistance the second-highest funding priority in the plan, with $4.46 billion earmarked for broad-spectrum antimicrobials, according to a Thursday Australian bourse filing.The funding aims to help antimicrobial candidates through each development stage, from preclinical research through to clinical trials and regulatory approval.The firm's RECCE 327 treatment candidate has shown activity against a number of pathogen classes under its existing US Department of War programs, the filing noted.Its shares rose 1% in recent trading on Thursday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4009":"广告","ASPR":"Adsouth Partners, Inc.","RCE.AU":"RECCE PHARMACEUTICALS LTD","BK7096":"制药"},"translate_title":"Recce Pharmaceuticals 有望从美国 ASPR 医疗对策战略中受益","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ASPR":1.5,"RCE.AU":1},"content_text":"Recce Pharmaceuticals (ASX:RCE) said it was well positioned to benefit from the US Administration for Strategic Preparedness and Response's (ASPR) new five-year medical countermeasures funding strategy, which ranked antimicrobial resistance the second-highest funding priority in the plan, with $4.46 billion earmarked for broad-spectrum antimicrobials, according to a Thursday Australian bourse filing.The funding aims to help antimicrobial candidates through each development stage, from preclinical research through to clinical trials and regulatory approval.The firm's RECCE 327 treatment candidate has shown activity against a number of pathogen classes under its existing US Department of War programs, the filing noted.Its shares rose 1% in recent trading on Thursday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}